Teva Pharmaceutical Industries

Latest Headlines

Latest Headlines

Teva's late-stage Huntington's drug scores 'breakthrough' bragging rights at FDA

Eight months after Teva scooped up the promising SD-809 (deutetrabenazine) to correct a severe movement disorder afflicting some 500,000 patients in the U.S., the company has scored bragging rights to the FDA's breakthrough drug designation.

Teva snaps up Gecko and its 'smart inhaler' to pump up respiratory meds

Getting patients to stick to their meds is a big problem in treating pulmonary diseases. So to boost adherence for its respiratory portfolio, Teva Pharmaceuticals is turning to technology.

Mapi Pharma makes third attempt to list on Nasdaq

Having tried and failed twice to pull off an IPO on Nasdaq, Israeli biopharma Mapi Pharma has arrived on Wall Street yet again in pursuit of $57.5 million (€51.2 million) to funnel into development of its once-a-month version of Teva's Copaxone.

AbbVie scores one against FTC in pay-for-delay AndroGel suit

AbbVie escaped the wrath of the FTC in a pay-for-delay suit over AndroGel generics, as a federal judge who previously threw out antitrust claims against the company rejected the agency's attempts to reconsider its case.  

Teva ratchets up its M&A pressure on Mylan with larger stake

Teva has upped its Mylan stake yet again--this time, passing a critical threshold that could help it pose a legal challenge to its generics rival.

Mapi Pharma closes $10M Series A round after two scuttled IPOs

Mapi Pharma has closed a $10 million (€9 million) Series A round to finance mid-phase trials of its once-a-month version of Teva's blockbuster multiple sclerosis drug, Copaxone. The round follows two aborted attempts to raise cash in a Nasdaq IPO.

Israel's Teva completes Auspex deal, has new arguments on Mylan offer

Teva Pharmaceutical Industries said it has completed its $3.2 billion acquisition of Auspex Pharmaceuticals, a U.S.-based biopharmaceutical company specializing in development of nervous-system therapies.

With Teva out, OncoGenex shrinks its PhIII lung cancer study

Yesterday, Teva formally tied off its collaboration with Seattle-based OncoGenex after handing over a $23 million payment as it exited a partnership to develop the biotech's late-stage cancer drug custirsen. Today, OncoGenex took the next step in its survival plan, trimming down the size and length of an ongoing trial as it reorganizes in the face of a major setback.

Israeli court tells Teva to return Copaxone, pay Proneuron; more ammo for Mylan?

An Israeli court ordered Teva Pharmaceutical to not only return the Copaxone (glatiramer acetate) multiple sclerosis drug it licensed from Proneuron Biotechnologies but also return 14 indications it received for other nervous system drugs. Oh, and pay Proneuron the equivalent of $128,666 as well.

Bayer to close vet med plant, lay off 130

Bayer had hoped to sell a veterinary med plant in Missouri that it picked up a few years ago from Teva. But no one has come forward, so the German drugmaker will close the plant and lay off 130 people.